Press Releases

Bethesda, Maryland, August 10, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) reminded markets, in response to recent investor concerns about Dendreon’s Provenge immune therapy, that NWBT’s DCVax® immune therapies for a broad range of cancers (including prostate, brain, ovarian and others) hold the promise, based on available data to date, of being cost effective and priced below other immune therapies while still providing... Read More

Bethesda, Maryland, August 4, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has expanded its number of clinical trial sites, and now has 12 sites across the U.S. open and active, where patients can enroll in the Company’s ongoing clinical trial of DCVax®immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company also announced that a substantial number of additional... Read More

Investment Follows Recent $3 Million Whitebox Hedge Fund Investment and $25 Million Equity Facility Agreement With Toucan Partners Bethesda, MD, July 8, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) (“NWBT”) announced today a $4.55 million equity investment on June 28, 2011, by The Richard M. Schulze Family Foundation (the “Foundation”). The sale of newly issued common stock of the Company to the... Read More

Northwest Biotherapeutics Announces Change and Expansion of Management Team Bethesda, Maryland, June 8, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has made changes and substantially expanded its management team, adding several highly experienced executives. Ms. Linda Powers, who has served as Chairman of the Board since May 2007, has been appointed Chief Executive Officer. Dr. Anthony Maida, a well known... Read More

$3 Million Initial Funding, and Up To $25 Million Further Funding On Fixed, Favorable Terms Bethesda, Maryland, June 5, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has put in place a series of financing arrangements, including a $3 million investment already received, and access to up to $25 million of further funding on fixed, specified and favorable terms, at such times and in such amounts as the Company... Read More